An Oxford company which aims to improve lung cancer diagnosis and treatment has been backed with 拢3.25 million funding.
When applied to CT scans, Optellum鈥檚 revolutionary platform enables doctors to diagnose, treat and cure patients at the earliest stages of the disease.
As well as identifying at-risk patients, the software may also minimize over-diagnosis and over-treatment of harmless lesions, thereby reducing the instances of unnecessary costly and invasive procedures.
A 拢1m investment from Luminous Ventures is part of a seed follow-on round of 拢3.25m which also includes IQ Capital, St. John鈥檚 College, Oxford and the family office of Sir Martin & Lady Audrey Wood.
Lomax Ward, general partner and co-founder of Luminous Ventures, said: 鈥淲e back technology that matters, so we are absolutely delighted to be investing in a breakthrough technology that is going to have such a significant impact improving the lives of lung cancer sufferers.
鈥淲e are thrilled to include Optellum amongst our growing portfolio of ground-breaking companies.鈥�